Last updated 15 days ago

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

20000 patients around the world

Available in Chile, Argentina, Brazil

Janssen Research & Development, LLC

75Research sites

20000Patients around the world

This study is for people with

Cardiac arrhythmia

Atrial fibrillation

From 18 Years

All Gender

: Minimum age of 18 years
Medically stable and appropriate for chronic antithrombotic treatment
Atrial fibrillation eligible to receive anticoagulation
Participant must satisfy one or both of the following categories of risk factors (a or b):
a) one or more of the following risk factors: i) age greater than or equal to 75 years, ii) history of a clinical symptomatic stroke.
b) two or more of the following risk factors: i) age between 65 and 74 years, ii) hypertension, iii) diabetes mellitus, iv) atherosclerotic vascular disease, v) heart failure

: Hemodynamically significant valve disease or those with valve disease that will potentially require surgical valve replacement during the study
Any condition other than AF that requires chronic anticoagulation